Page 30 - Priority Review News Today

​​​​​​​Earlier today, UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization to Vertex Pharmaceuticals and CRISPR Therapeutics for...

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Nov 16, 2023--

Four near-term milestones, including initiation of potential spinout initiatives expected in 2023/early 2024 Completing enrollment of the originally-targeted...

Breyanzi (lisocabtagene maraleucel) is under Priority Review for the treatment of adult patients with relapsed or refractory CLL or SLL.

New analyses from the phase 3 MAESTRO-NASH support the oral daily drug's benefit for cardiovascular and hormonal outcomes over 1 year.

The FDA approved Takeda Pharmaceutical Co Ltd's (NYSE:

The on-demand enzyme replacement therapy reduced acute thrombotic thrombocytopenic purpura events in patients who experience potentially fatal blood clotting.

UCB receives CHMP positive opinion for rozanolixizumab for treatment of adults with generalized myasthenia gravis in Europe The Committee for Medicinal...

— FRUZAQLA is the first targeted therapy approved in the U.S. for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in more than a decade — — U.S....

A weight management drug was approved for patients with obesity or who are overweight with at least one weight-related condition, like OSA.